Based on the BEACON CRC trial, the combination of the anti‐EGFR antibody cetuximab and the BRAF inhibitor encorafenib is now approved in BRAF mutated mCRC after progressing on first‐line chemotherapy. The gene discussed is EGFR; the disease is colorectal carcinoma.